This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Eli Lilly's ASH25 data for Jaypirca's PFS benefit in treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL)
Ticker(s): LLYWho's the expert?
Institution: Texas Oncology
- Medical Oncologsist at Texas Oncology.
- Manages 15 Myelofibrosis patients per year.
- Fellowship trained at in Hematology/Oncology at Louisiana State University Health Sciences; diplomat of the American Board of Internal Medicine.
Interview GoalThis conversation will focus on the treatment landscape and potential use of Jaypirca in CLL and SLL.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
